XBIO — Xenetic Biosciences Cashflow Statement
0.000.00%
- $6.41m
- -$1.41m
- $2.54m
- 49
- 43
- 38
- 39
Annual cashflow statement for Xenetic Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -12.8 | -10.9 | -5.65 | -6.55 | -4.13 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 7.25 | 9.6 | 0.446 | 2.33 | 0.283 |
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -0.882 | -0.052 | 0.461 | -0.427 | -0.263 |
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -6.4 | -4.27 | -4.74 | -4.65 | -4.11 |
Capital Expenditures | — | — | — | -0.5 | 0 |
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 0.002 | 0 | — | — | — |
Sale of Fixed Assets | |||||
Cash from Investing Activities | 0.002 | 0 | — | -0.5 | 0 |
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 16.1 | 5.43 | 11.5 | 0 | — |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 9.73 | 1.16 | 6.72 | -5.15 | -4.11 |